| Pharmacokinetics of intravitreal bevacizumab (Avastin) SJ Bakri, MR Snyder, JM Reid, JS Pulido, RJ Singh Ophthalmology 114 (5), 855-859, 2007 | 877 | 2007 |
| CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism J Camacho-Pereira, MG Tarragó, CCS Chini, V Nin, C Escande, ... Cell metabolism 23 (6), 1127-1139, 2016 | 790 | 2016 |
| Pharmacokinetics of intravitreal ranibizumab (Lucentis) SJ Bakri, MR Snyder, JM Reid, JS Pulido, MK Ezzat, RJ Singh Ophthalmology 114 (12), 2179-2182, 2007 | 663 | 2007 |
| Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent CR Patra, R Bhattacharya, E Wang, A Katarya, JS Lau, S Dutta, M Muders, ... Cancer research 68 (6), 1970-1978, 2008 | 446 | 2008 |
| Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles RR Arvizo, OR Miranda, DF Moyano, CA Walden, K Giri, R Bhattacharya, ... PloS one 6 (9), e24374, 2011 | 422 | 2011 |
| Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study E Galanis, KA Jaeckle, MJ Maurer, JM Reid, MM Ames, JS Hardwick, ... Journal of clinical oncology 27 (12), 2052-2058, 2009 | 399 | 2009 |
| Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames, L Jia, M Weil, ... Cancer research 71 (17), 5626-5634, 2011 | 306 | 2011 |
| Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial KL Davis, E Fox, MS Merchant, JM Reid, RA Kudgus, X Liu, CG Minard, ... The Lancet Oncology 21 (4), 541-550, 2020 | 274 | 2020 |
| Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study JLG Bender, PC Adamson, JM Reid, L Xu, S Baruchel, Y Shaked, ... Journal of clinical oncology 26 (3), 399-405, 2008 | 272 | 2008 |
| Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study EA Raetz, MS Cairo, MJ Borowitz, SM Blaney, MD Krailo, TA Leil, JM Reid, ... Journal of Clinical Oncology 26 (22), 3756-3762, 2008 | 258 | 2008 |
| Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group S Malempati, B Weigel, AM Ingle, CH Ahern, JM Carroll, CT Roberts, ... Journal of Clinical Oncology 30 (3), 256-262, 2012 | 212 | 2012 |
| Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report M Fouladi, JR Park, CF Stewart, RJ Gilbertson, P Schaiquevich, J Sun, ... Journal of Clinical Oncology 28 (22), 3623-3629, 2010 | 200 | 2010 |
| Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1 JM Reid, MJ Kuffel, JK Miller, R Rios, MM Ames Clinical Cancer Research 5 (8), 2192-2197, 1999 | 189 | 1999 |
| Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I … JL Glade Bender, A Lee, JM Reid, S Baruchel, T Roberts, SD Voss, B Wu, ... Journal of clinical oncology 31 (24), 3034-3043, 2013 | 168 | 2013 |
| Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group B Weigel, S Malempati, JM Reid, SD Voss, SY Cho, HX Chen, M Krailo, ... Pediatric blood & cancer 61 (3), 452-456, 2014 | 163 | 2014 |
| Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709) JG Villablanca, MD Krailo, MM Ames, JM Reid, GH Reaman, ... Journal of clinical oncology 24 (21), 3423-3430, 2006 | 159 | 2006 |
| Phase I study of the Aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new … SG DuBois, A Marachelian, E Fox, RA Kudgus, JM Reid, S Groshen, ... Journal of Clinical Oncology 34 (12), 1368-1375, 2016 | 146 | 2016 |
| Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors HC Pitot, EA McElroy Jr, JM Reid, AJ Windebank, JA Sloan, C Erlichman, ... Clinical cancer research 5 (3), 525-531, 1999 | 146 | 1999 |
| Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors AA Adjei, C Erlichman, JA Sloan, JM Reid, HC Pitot, RM Goldberg, ... Journal of clinical oncology 18 (8), 1748-1757, 2000 | 143 | 2000 |
| A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 … ML Loh, SK Tasian, KR Rabin, P Brown, D Magoon, JM Reid, X Chen, ... Pediatric blood & cancer 62 (10), 1717-1724, 2015 | 135 | 2015 |
